C14orf45 Activators
C14orf45 Activators are a diverse group of compounds that enhance the protein's activity through various signaling cascades, mainly involving phosphorylation events. The activation of adenylyl cyclase by certain activators elevates intracellular cAMP, which in turn activates protein kinase A (PKA). PKA is known to phosphorylate a wide range of proteins, and this phosphorylation can enhance the function of C14orf45, which is crucial for basal body orientation. Similarly, other activators work by increasing intracellular calcium levels, activating calmodulin-dependent kinases, which may also phosphorylate and thus activate C14orf45. This is particularly significant as the phosphorylation status of C14orf45 can modulate its interaction with other proteins involved in the orientation of basal bodies.
Additionally, specific activators that inhibit phosphodiesterases result in an accumulation of cAMP, further potentiating PKA activity and the downstream phosphorylation of C14orf45. Inhibition of protein phosphatases byother compounds leads to a net increase in the phosphorylation of cellular proteins, which could include C14orf45, thereby enhancing its activity. Moreover, some activators indirectly stimulate stress-activated protein kinases, which are capable of phosphorylating and activating C14orf45, thereby influencing its functional role. Furthermore, changes in protein prenylation and membrane localization induced by certain inhibitors can also lead to the activation of C14orf45, as the protein's function is closely tied to its spatial dynamics within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which is known to phosphorylate a myriad of proteins. PKC-mediated phosphorylation could increase the activity of C14orf45 by modifying its interaction with other basal body orientation proteins. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 acts as a calcium ionophore, increasing intracellular calcium levels. Elevated calcium can activate calmodulin-dependent kinases, which may phosphorylate and activate C14orf45 as part of the basal body orientation process. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin serves as a calcium ionophore similar to A23187, raising intracellular calcium concentrations. This increase can stimulate calcium-dependent kinases, potentially leading to the phosphorylation and activation of C14orf45. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that increases cAMP levels within cells by stimulating adrenergic receptors. The subsequent activation of PKA may indirectly activate C14orf45 by phosphorylation, facilitating its role in basal body orientation. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases, leading to increased cAMP levels by preventing its breakdown. Elevated cAMP can activate PKA, which could then phosphorylate and enhance the activity of C14orf45. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic acid inhibits protein phosphatases PP1 and PP2A, leading to increased phosphorylation levels of cellular proteins. This inhibition may indirectly result in the enhanced phosphorylation and activation of C14orf45. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that also activates stress-activated protein kinases such as JNK. Activation of these kinases could lead to the phosphorylation and functional enhancement of C14orf45. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A sc-24000B sc-24000C | 10 µg 100 µg 500 µg 1 mg | $160.00 $750.00 $1400.00 $3000.00 | 59 | |
Calyculin A is a potent inhibitor of protein phosphatases PP1 and PP2A, similar to okadaic acid. Inhibition of these phosphatases may result in increased phosphorylation and activation of C14orf45. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $97.00 $224.00 | 30 | |
8-Bromo-cAMP is a cell-permeable analog of cAMP that activates PKA. PKA can phosphorylate various substrates, possibly including C14orf45, leading to its activation in the context of basal body orientation. | ||||||
Mevastatin (Compactin) | 73573-88-3 | sc-200853 sc-200853A | 10 mg 50 mg | $75.00 $175.00 | 18 | |
Mevastatin is an HMG-CoA reductase inhibitor that can lead to changes in prenylation of proteins, affecting their membrane localization and function. This could indirectly activate C14orf45 by altering its localization or interaction with other proteins involved in basal body orientation. | ||||||